Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome

A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 rug/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrom...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of infectious diseases Vol. 164; no. 6; pp. 1119 - 1127
Main Authors:	Huggins, John W., Hsiang, Chin Min, Cosgriff, Thomas M., Guang, Mei Ying, Smith, Joseph I., Wu, Zhen Ou, LeDuc, James W., Zheng, Zhi Ming, Meegan, James M., Wang, Qi Nan, Oland, Dwayne D., Gui, Xi En, Gibbs, Paul H., Yuan, Guang Hui, Zhang, Tian Ming
Format:	Journal Article
Language:	English
Published:	United States The University of Chicago Press 01-12-1991 University of Chicago Press
Subjects:	Anemia, Hemolytic - chemically induced Antivirals Death Double-Blind Method Epidemiology Female Fever - drug therapy Fever - etiology Follow-Up Studies Hantavirus - immunology Hemorrhage Hemorrhagic fever with renal syndrome Hemorrhagic Fever with Renal Syndrome - complications Hemorrhagic Fever with Renal Syndrome - drug therapy Hemorrhagic Fever with Renal Syndrome - mortality Humans Hypotension - drug therapy Hypotension - etiology Immunoglobulin M - blood Injections, Intravenous Life Tables Male Mortality Oliguria Oliguria - drug therapy Oliguria - etiology Placebos Polyuria - drug therapy Polyuria - etiology Prognosis Prospective Studies Regression Analysis Ribavirin - administration & dosage Ribavirin - adverse effects Ribavirin - therapeutic use Teaching hospitals Urine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	A prospective, randomized, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin (loading dose of 33 mg/kg, 16 mg/kg every 6 h for 4 days, and 8 rug/kg every 8 h for 3 days) was conducted in 242 patients with serologically confirmed hemorrhagic fever with renal syndrome (HFRS) in the People's Republic of China. Mortality was significantly reduced (sevenfold decrease in risk) among ribavirin-treated patients, when comparisons were adjusted for baseline risk estimators of mortality (P = .01; two-tailed). HFRS typically consists of five consecutive but frequently overlapping clinical phases. Only occurrence of oliguric phase and hemorrhage was associated with severity of clinical disease in the placebo group. Ribavirin therapy also resulted in a significant reduction in the risk ofentering the oliguric phase and experiencing hemorrhage. The only ribavirin-related side effect was a well-recognized, fully reversible anemia after completion of therapy.
Bibliography:	ark:/67375/HXZ-56MFHK1T-X istex:35B9092D2A21C4EC93CEFE95BB7C96B58029F91D Present addresses: Department of Oncology, Fitzsimmons Army Center, Denver, Colorado (T.M.C.); World Health Organization, Geneva, Switzerland (J.M.M.). Reprints or correspondence: Dr. John W. Huggins, Department of Antiviral Studies, Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702-5011. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0022-1899 1537-6613
DOI:	10.1093/infdis/164.6.1119